Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM). This compound promotes early fungal apoptosis within the cell cycle, diminishes intracellular concentrations of IL-2, NLRP3, and NF-κBp65 proteins, incites mitochondrial impairment and ROS accumulation, and culminates in fungal cell lysis and death [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM). This compound promotes early fungal apoptosis within the cell cycle, diminishes intracellular concentrations of IL-2, NLRP3, and NF-κBp65 proteins, incites mitochondrial impairment and ROS accumulation, and culminates in fungal cell lysis and death [1]. |
Molecular Weight | 468.55 |
Formula | C27H28N6O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CYP51/PD-L1-IN-3 inhibitor inhibit